Reports Q1 revenue $41.1M, consensus $56.7M. The company states: ” The year-over-year decrease in total revenue reflects a change in AbbVie’s gross-to-net rebate reserves in the first quarter of 2025, which is expected to impact the quarterly phasing of LINZESS U.S. net sales in 2025 but is not expected to impact the full-year results. See U.S. Brand Collaboration section of this press release above for further explanation.” Ironwood (IRWD) ended the first quarter of 2025 with $108.5 million of cash and cash equivalents, compared to $88.6 million of cash and cash equivalents at the end of 2024. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize stockholder value across all areas of the business, including advancing plans for a confirmatory Phase 3 trial for apraglutide and exploring strategic alternatives,” said Tom McCourt, chief executive officer of Ironwood.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood Pharma: Hold Rating Maintained Amid Revenue Uncertainty and Long-term Concerns
- IRWD Earnings this Week: How Will it Perform?
- Ironwood backs FY25 revenue view $260M-$290M, consensus $287.07M
- Ironwood downgraded to Hold from Buy at Craig-Hallum
- Ironwood Pharma: Hold Rating Amid Uncertainty Over Apraglutide’s Phase 3 Trial and Strategic Options